ALPHARETTA, Ga., Oct. 23, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2024 on Wednesday, Oct. 30 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day.The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer.To join ...

Avanos Medical (AVNS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Si ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they beli ...

Avanos Medical, Inc. (AVNS) is well-poised for growth in the coming quarters, courtesy of its impressive product line. The optimism led by a solid fiscal second-quarter 2024 performance and continued focus on its research and development (R&D) are expected to contribute further. However, macroeconomic concerns and foreign exchange volatility persist.In the year-to-date period, this Zacks Rank #2 (Buy) stock has gained 3.7% compared with the 8.4% rise of the industry and 20% growth of the S&P 500 Composite.T ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued ...

Avanos Medical’s (AVNS) state-of-the-art recovery system brand, GAME READY, recently announced a new partnership with NFL defensive end and San Francisco 49ers star, Nick Bosa. As part of this partnership, GAME READY has been named the Official Recovery Partner of Nick Bosa. This collaboration is a paid partnership between Avanos Medical and Nick Bosa.Avanos Medical’s GAME READY provides innovative, multi-modality recovery systems for injury treatment and physical therapy. The brand’s products are used by t ...

ALPHARETTA, Ga., Sept. 9, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, senior vice president, chief financial officer, and chief transformation officer will participate in a fireside chat at CL King's virtual 22nd Annual Best Ideas Conference 2024 on Mon., Sept. 16 at approximately 9:30 a.m. Eastern Time.A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site.About Avan ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving ...

Avanos Medical, Inc. (AVNS) reported second-quarter 2024 adjusted earnings per share (EPS) from continuing operations of 34 cents, up 41.7% year over year. The bottom line surpassed the Zacks Consensus Estimate by 17.2%.GAAP EPS from continuing operations in the quarter under review was 9 cents against the year-ago period’s loss of 9 cents per share.RevenuesRevenues grossed $171.7 million in the reported quarter, up 1.4% year over year. The metric beat the Zacks Consensus Estimate by 0.4%.Organic sales were ...

Financial Data and Key Metrics Changes - For Q2 2024, the company reported sales from continuing operations of approximately $172 million, with organic sales up 2.6% year-over-year [7][17] - Adjusted diluted earnings per share were $0.34, and adjusted EBITDA from continuing operations was approximately $27 million [7][17] - Adjusted EBITDA grew by 17% compared to the previous year, with an adjusted EBITDA margin expansion of 210 basis points [17][18] Business Line Data and Key Metrics Changes - The Digestive Health portfolio grew almost 9% organically compared to the prior year, driven by strong demand for the NeoMed product line [8][9] - The Pain Management and Recovery portfolio saw normalized organic sales up approximately 2%, with the On-Q/ambIT portfolio growing by mid single-digits [10][12] - The Game Ready portfolio demonstrated strong momentum with double-digit growth for two consecutive quarters [11][12] Market Data and Key Metrics Changes - The international business for Digestive Health grew 11% for the quarter, indicating strong global demand [32] - The HA portfolio experienced a decline of more than 30% year-over-year but is expected to stabilize around $42 million annualized [12][27] Company Strategy and Development Direction - The company is focused on four key transformation priorities: optimizing the organization, transforming the product portfolio, enhancing operating profitability, and efficient capital allocation [13][14] - The company aims for consistent mid single-digit growth, targeting organic revenue of approximately $730 million by 2025, with gross margins surpassing 60% [20][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid single-digit growth for the Pain Management business in the long term, despite current challenges [25][26] - The company anticipates continued improvement in free cash flow, projecting approximately $70 million for 2024 [21] Other Important Information - The company maintains a strong balance sheet with $92 million in cash and $175 million in debt, keeping leverage levels below one turn [20] - Free cash flow was positive at $22 million for the quarter, with expectations for continued improvement in the second half of the year [21] Q&A Session Summary Question: Pain Management growth outlook and HA progress - Management indicated mid single-digit growth is possible for the Pain business moving into 2025, with positive momentum in the Surgical Pain business and Game Ready [25][26] Question: Reimbursement for On-Q - Management noted that a unique code for On-Q could potentially restore the business to previous peak levels, though immediate impacts are uncertain [29] Question: Digestive Health and NeoMed conversion - Management expects NeoMed to remain a high single-digit grower, with upcoming product launches expected to enhance growth [32][33] Question: M&A strategy and share buyback - Management confirmed ongoing financial discipline in M&A, with a robust pipeline focused on Digestive Health, and mentioned past share buybacks without announcing new programs [36][39]